These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 29132557)

  • 1. Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?
    Chaudhary LN; Wilkinson KH; Kong A
    Surg Oncol Clin N Am; 2018 Jan; 27(1):141-153. PubMed ID: 29132557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early stage triple negative breast cancer: Management and future directions.
    Chaudhary LN
    Semin Oncol; 2020 Aug; 47(4):201-208. PubMed ID: 32507668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
    Zhao Y; Schaafsma E; Cheng C
    Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Gonçalves A
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
    Steenbruggen TG; van Ramshorst MS; Kok M; Linn SC; Smorenburg CH; Sonke GS
    Drugs; 2017 Aug; 77(12):1313-1336. PubMed ID: 28616845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.
    Jin Z; Wang W; Jiang N; Zhang L; Li Y; Xu X; Cai S; Wei L; Liu X; Chen G; Zhou Y; Liu C; Li Z; Jin F; Chen B
    PLoS One; 2015; 10(7):e0130286. PubMed ID: 26196284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer.
    Man VC; Cheung PS
    Hong Kong Med J; 2017 Jun; 23(3):251-7. PubMed ID: 28484080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer.
    Tung NM; Winer EP
    J Clin Oncol; 2015 Mar; 33(9):969-71. PubMed ID: 25559817
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
    Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
    Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data.
    Patel SA; DeMichele A
    Curr Oncol Rep; 2017 Aug; 19(8):56. PubMed ID: 28733827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer.
    Miglietta F; Dieci MV; Griguolo G; Guarneri V
    Cancer Treat Rev; 2021 Jul; 98():102222. PubMed ID: 34023642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.
    Carey LA
    Clin Cancer Res; 2015 Sep; 21(18):4027-9. PubMed ID: 26374072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives.
    Carbognin L; Furlanetto J; Vicentini C; Nortilli R; Pilotto S; Brunelli M; Pellini F; Pollini GP; Bria E; Tortora G
    Anticancer Agents Med Chem; 2015; 15(1):15-25. PubMed ID: 25329488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
    Nabholtz JM; Chalabi N; Radosevic-Robin N; Dauplat MM; Mouret-Reynier MA; Van Praagh I; Servent V; Jacquin JP; Benmammar KE; Kullab S; Bahadoor MR; Kwiatkowski F; Cayre A; Abrial C; Durando X; Bignon YJ; Chollet P; Penault-Llorca F
    Int J Cancer; 2016 May; 138(9):2274-80. PubMed ID: 26649807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
    Denkert C; von Minckwitz G; Brase JC; Sinn BV; Gade S; Kronenwett R; Pfitzner BM; Salat C; Loi S; Schmitt WD; Schem C; Fisch K; Darb-Esfahani S; Mehta K; Sotiriou C; Wienert S; Klare P; André F; Klauschen F; Blohmer JU; Krappmann K; Schmidt M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Untch M; Loibl S
    J Clin Oncol; 2015 Mar; 33(9):983-91. PubMed ID: 25534375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
    Agrawal LS; Mayer IA
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):654-8. PubMed ID: 25658890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.
    Stover DG; Winer EP
    Breast; 2015 Nov; 24 Suppl 2():S132-5. PubMed ID: 26255198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.